Similar findingswere reported in previous studies where biodistribution of PEG–Gal-coatedgold nanoparticles (ASGPR-targeted) were compared with nonreceptor-specificcitrate-coated gold nanoparticles in an in vivo rodentmodel. The preferential tumor accumulationin the present study was evident from the observation where tumorshad 1.6 times higher AG-AuNPs uptake compared to nontumor liver tissue.This selective localization in liver emphasized the impact of arabinogalactanfunctionalization on nanoparticle biodistribution at the therapeuticlevel. The gene discussed is ASGR1; the disease is neoplasm.